Paclitaxel, Carboplatin, and Topotecan in Patients With Ovarian Cancer

Inclusion Criteria: * Histologically proven epithelial carcinoma of the ovary or of the fallopian tube or extraovarian papillary serous carcinoma with extent to the ovary * International Federation of Gynecology and Obstetrics (FIGO) stage IIB-IV, regardless of measurable or non-measurable disease * No prior chemo- or radiotherapy * Adequate hematologic, renal and hepatic function: * ANC ≥ 1.5 x 10\^9/L, * Platelet counts ≥ 100 x 10\^9/L, * Total bilirubin ≤ 1.5 x upper normal limit, * Alkaline Phosphatase ≤ 3 x upper normal limit, * Serum creatinine ≤ 1.25 upper normal limit, * Estimated GFR ≥ 60 ml/min * Performance status 0-2 (ECOG) * Life expectancy must be greater than 12 weeks Exclusion Criteria: * Non-epithelial tumors or mixed epithelial/non-epithelial tumors (e.g. mixed Mullerian tumors) or tumors of low malignant potential (borderline tumors) * Prior treatment with chemo- or radiotherapy * Administration of other simultaneous chemotherapeutic drugs or hormonal therapy or simultaneous radiotherapy during the study treatment period or planned whole abdominal radiotherapy * History of congestive heart failure * Symptomatic brain metastasis * Complete bowel obstruction * Dementia * Active infection or other serious underlying medical condition * Pre-existing motor or sensory neurologic pathology